Ruben Niesvizky

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. ncbi request reprint Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features
    Ruben Niesvizky
    New York Presbyterian Hospital, Weill Medical College of Cornell University, NY 10021, USA
    Leuk Lymphoma 43:607-12. 2002
  2. ncbi request reprint Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Leuk Lymphoma 48:2330-7. 2007
  3. pmc Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
    Ruben Niesvizky
    Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 19:2248-56. 2013
  4. pmc Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 19:1534-46. 2013
  5. pmc BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
    Adriana Rossi
    Division of Hematology and Medical Oncology, Department of Medicine, Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Blood 121:1982-5. 2013
  6. ncbi request reprint Novel therapies in monoclonal gammopathies
    Ruben Niesvizky
    Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
    Hematology 17:S121-4. 2012
  7. ncbi request reprint Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York Presbytarian Hospital Cornell Medical Center, New York, NY 10021, USA
    Br J Haematol 138:640-3. 2007
  8. ncbi request reprint BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
    Blood 111:1101-9. 2008
  9. doi request reprint The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
    Ruben Niesvizky
    Weill Cornell Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    Br J Haematol 143:46-53. 2008
  10. ncbi request reprint Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia
    Ruben Niesvizky
    Weill Cornell Medical College, New York, New York 10021, USA
    J Natl Compr Canc Netw 8:S13-20. 2010

Detail Information

Publications48

  1. ncbi request reprint Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features
    Ruben Niesvizky
    New York Presbyterian Hospital, Weill Medical College of Cornell University, NY 10021, USA
    Leuk Lymphoma 43:607-12. 2002
    ..005). We conclude that this regimen is safe and effective. A rapid response may be useful in selecting patients who may benefit from further high dose chemotherapy and stem cell support...
  2. ncbi request reprint Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Leuk Lymphoma 48:2330-7. 2007
    ..Low-dose aspirin appears to reduce the incidence of thrombosis with these regimens. Routine use of aspirin as antithrombotic prophylaxis in MM patients receiving immunomodulatory drugs with corticosteroids is warranted...
  3. pmc Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
    Ruben Niesvizky
    Weill Cornell Medical College, New York, New York, USA
    Clin Cancer Res 19:2248-56. 2013
    ....
  4. pmc Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York 10021, USA
    Clin Cancer Res 19:1534-46. 2013
    ....
  5. pmc BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
    Adriana Rossi
    Division of Hematology and Medical Oncology, Department of Medicine, Myeloma Center, Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY 10021, USA
    Blood 121:1982-5. 2013
    ..BiRd remains a highly potent and safe regimen for frontline therapy in patients with MM without apparent increase in risk of SPMs. This trial was registered at www.clinicaltrials.gov as #NCT00151203...
  6. ncbi request reprint Novel therapies in monoclonal gammopathies
    Ruben Niesvizky
    Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
    Hematology 17:S121-4. 2012
    ..Novel immunomodulating drugs, proteasome inhibitors and monoclonal antibodies will be highlighted...
  7. ncbi request reprint Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York Presbytarian Hospital Cornell Medical Center, New York, NY 10021, USA
    Br J Haematol 138:640-3. 2007
    ..Caution should be exercised when lenalidomide therapy is commenced and CrCl should be incorporated as a determinant of the initial dosing of lenalidomide in MM patients...
  8. ncbi request reprint BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
    Ruben Niesvizky
    Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
    Blood 111:1101-9. 2008
    ..BiRD is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed multiple myeloma. This trial was registered at www.clinicaltrials.gov as #NCT00151203...
  9. doi request reprint The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
    Ruben Niesvizky
    Weill Cornell Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    Br J Haematol 143:46-53. 2008
    ..In conclusion, bortezomib had substantial activity in relapsed myeloma patients; CR may be a surrogate marker for significant clinical benefit with bortezomib. MR appeared to be valid as a separate response category in this setting...
  10. ncbi request reprint Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia
    Ruben Niesvizky
    Weill Cornell Medical College, New York, New York 10021, USA
    J Natl Compr Canc Netw 8:S13-20. 2010
    ....
  11. ncbi request reprint Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant
    Ruben Niesvizky
    Weill Cornell Medical College, New York, NY 10021, USA
    Oncology (Williston Park) 24:14-21. 2010
    ..Toxicity profiles differ among the newly established and emerging regimens, and oncology teams must take care to apply the appropriate risk management measures, including dose reduction where necessary...
  12. pmc Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma
    Ruben Niesvizky
    Department of Medicine, Division of Hematology Oncology, Center of Excellence of Lymphoma and Myeloma, Weill Cornell Medical College New York Presbyterian Hospital, New York, New York, USA
    Cancer 117:336-42. 2011
    ..Romidepsin is an HDAC inhibitor that exhibits antiproliferative and apoptotic effects against multiple myeloma cell lines...
  13. pmc Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma
    Tomer Mark
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, New York 10021, USA
    Biol Blood Marrow Transplant 14:795-8. 2008
    ..91). In conclusion, Cy can be added to G-CSF for stem cell mobilization to successfully overcome the suppressive effect of prior treatment with lenalidomide...
  14. ncbi request reprint Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Alan D Dosik
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 106:616-22. 2006
    ..Hematologic reserve after radioimmunotherapy (RIT) is an important consideration when subsequent therapy is required...
  15. doi request reprint Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
    Sundar Jagannath
    St Vincent s Comprehensive Cancer Center, New York, NY 10011, USA
    Br J Haematol 143:537-40. 2008
    ..3 mg/m(2) is preferred. If bortezomib dose reduction is required, the 1.0 mg/m(2) dose still offers patients a substantial survival benefit...
  16. doi request reprint Outcome of deferred initial therapy in mantle-cell lymphoma
    Peter Martin
    Starr Building Rm 340, Weill Cornell Medical College and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 27:1209-13. 2009
    ..Because data on observation, or "watch and wait," have not been previously reported, we analyzed the outcome of deferred initial therapy...
  17. pmc Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
    Tomer Mark
    Department of Medicine, Division of Hematology and Medical Oncology, Center of Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
    Br J Haematol 143:654-60. 2008
    ..This is the first time this phenomenon has been seen with regularity in non-myeloablative therapy for MM. Analogous to the ASCT experience, ASIPs do not signal incipient disease progression, but rather herald robust response...
  18. ncbi request reprint Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy
    Morton Coleman
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10021, USA
    Cancer 112:2228-32. 2008
    ..Many patients with recurrent lymphoma are unable to tolerate intensive therapies, or have disease that is refractory. Metronomic chemotherapy offers a novel, potentially less toxic yet effective treatment strategy...
  19. ncbi request reprint BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia
    Morton Coleman
    Specialized Center of Research for Multiple Myeloma, Weill Medical College of Cornell University and the Department of Medicine, New York Presbyterian Hospital Cornell Medical Center, New York, NY 10021, USA
    Leuk Lymphoma 43:1777-82. 2002
    ..Caution should be exercised when using thalidomide, alone or in combination, in patients with a preexisting tendency to thromboses, severe cardiopulmonary disease, or neurologic dysfunction...
  20. doi request reprint Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma
    Peter Martin
    Center for Lymphoma and Myeloma, Division of Hematology Oncology, Department of Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Hematol 45:126-32. 2008
    ..Each of these strategies has shown varying degrees of preclinical and clinical success. In this review we discuss the rationale for various strategies and report results from clinical trials employing these agents...
  21. pmc Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4
    Xiangao Huang
    Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
    Blood 120:1095-106. 2012
    ..Reversible inhibition of CDK4/CDK6 in sequential combination therapy thus represents a novel mechanism-based cancer therapy...
  22. pmc A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma
    Tomer M Mark
    Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA
    Biol Blood Marrow Transplant 19:831-7. 2013
    ..Bendamustine up to a dose of 225 mg/m(2) added to autologous stem cell transplantation conditioning with high-dose melphalan in patients with multiple myeloma did not exacerbate expected toxicities...
  23. ncbi request reprint Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone
    Morton Coleman
    Specialized Center of Research for Multiple Myeloma, Center for Lymphoma and Myeloma, Division of Hematology Oncology, Weill Medical College of Cornell University, New York, NY, USA
    Semin Oncol 30:270-4. 2003
    ..BLT-D is effective in WM. Because of its toxicity, predominantly neurological, BLT-D may best serve as an induction regimen or to "rescue" patients with refractory disease or disease-related low counts...
  24. pmc Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients
    Nikoletta Lendvai
    New York University Cancer Institute, New York University School of Medicine, New York, NY, USA
    Cancer Immun 10:4. 2010
    ..These data demonstrate that CTAgs, particularly CT7, are immunogenic in MM patients and merit further exploration as targets of immunological therapy in MM...
  25. doi request reprint CDK2 phosphorylation of Smad2 disrupts TGF-beta transcriptional regulation in resistant primary bone marrow myeloma cells
    Linda B Baughn
    Department of Pathology, Weill Medical College of Cornell University, New York, NY 10065, USA
    J Immunol 182:1810-7. 2009
    ....
  26. ncbi request reprint A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
    Linda B Baughn
    Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Res 66:7661-7. 2006
    ..PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers...
  27. ncbi request reprint Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Starr Bldg Rm 340, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 E 70th St, New York, NY 10021, USA
    J Clin Oncol 23:5696-704. 2005
    ..To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's lymphoma...
  28. ncbi request reprint Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma
    Tomer M Mark
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital Cornell Medical Center, New York, NY, USA Electronic address
    Leuk Res 38:517-24. 2014
    ..We also detail its clinical development, including establishment of the approved dose/schedule, phase 2 and 3 trials in relapsed and refractory patients, and novel pomalidomide-based combinations...
  29. pmc MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin
    Tricia Nardiello
    New York University Cancer Institute, New York University School of Medicine, New York, New York, USA
    Clin Cancer Res 17:4309-19. 2011
    ..In this report, we examine the mechanistic role of MAGE-A in promoting survival of proliferating multiple myeloma cells...
  30. ncbi request reprint Milatuzumab: a promising new agent for the treatment of lymphoid malignancies
    Tomer Mark
    Weill Medical College of Cornell University, New York Presbyterian Hospital Cornell Medical Center, Center for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, 525 East 68th Street, NY 10021, USA
    Expert Opin Investig Drugs 18:99-104. 2009
    ..The selective expression of CD74, the invariant chain of the MHC class II molecule, in these malignancies provides an attractive target for antibody-based therapy...
  31. doi request reprint Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
    Asher A Chanan-Khan
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 50:559-65. 2009
    ..The oblimersen/dexamethasone regimen was generally well tolerated with fatigue, fever and nausea, the most common adverse events reported...
  32. ncbi request reprint Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma
    Morton Coleman
    Division of Hematology Oncology, Department of Medicine, Center for Lymphoma and Myeloma, Weill Cornell Medical College, and New York Presbyterian Hospital, New York, NY, USA
    Leuk Lymphoma 49:447-50. 2008
    ....
  33. doi request reprint FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma
    Sarah C Rutherford
    Centre for Lymphoma and Myeloma, Division of Haematology Oncology, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY 10021, USA
    Leuk Lymphoma 49:719-26. 2008
    ..Our findings support a potential role for preoperative FDG-PET in consideration of the need for splenectomy in these settings...
  34. pmc International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
    Antonio Palumbo
    Antonio Palumbo and Alessandra Larocca, University of Torino, Torino Michele Cavo, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy S Vincent Rajkumar, Mayo Clinic, Rochester, MN Jesus F San Miguel, University Hospital of Salamanca, Salamanca, Spain Ruben Niesvizky, Weill Cornell Medical College, New York, NY Gareth Morgan, Royal Marsden Hospital, London, United Kingdom Ola Landgren, National Cancer Institute, Bethesda, MD Roman Hajek, University of Ostrava School of Medicine and University Hospital Ostrava, Ostrava, Czech Republic Hermann Einsele, University of Wurzburg, Wurzburg, Germany Kenneth C Anderson and Paul G Richardson, Dana Farber Cancer Institute, Boston, MA Meletios A Dimopoulos, University of Athens School of Medicine, Athens, Greece Andrew Spencer, Alfred Hospital, Melbourne, Victoria, Australia A Keith Stewart, Mayo Clinic, Scottsdale, AZ Kazuyuki Shimizu, Aichi Gakuin Hospital, Department of Physiology
    J Clin Oncol 32:587-600. 2014
    ..To provide an update on recent advances in the management of patients with multiple myeloma who are not eligible for autologous stem-cell transplantation...
  35. ncbi request reprint Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease
    Ruben Niesvizky
    Multiple Myeloma Service, Division of Hematology and Medical Oncology, New York Presbyterian Hospital, New York, NY 10021, USA
    Semin Oncol 30:20-4. 2003
    ..Further evaluation of gallium nitrate to attenuate progression of disease in patients with multiple myeloma is warranted...
  36. ncbi request reprint Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
    John P Leonard
    Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    J Clin Oncol 23:5044-51. 2005
    ..To explore the safety and therapeutic activity of combination anti-B-cell monoclonal antibody therapy in non-Hodgkin's lymphoma (NHL)...
  37. ncbi request reprint The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation
    Achim A Jungbluth
    New York Branch, Ludwig Institute for Cancer Research, New York, NY, USA
    Blood 106:167-74. 2005
    ..Furthermore, the common expression and correlation with proliferation suggest a possible pathogenic role for these proteins in myeloma...
  38. ncbi request reprint Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma
    Scott Ely
    Department of Pathology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Cancer Res 65:11345-53. 2005
    ..Mutually exclusive cdk4/cyclin D1 and cdk6/cyclin D2 pairing, therefore, is likely to be a critical determinant for cell cycle reentry and progression and may play a pivotal role in the expansion of self-renewing multiple myeloma cells...
  39. pmc Endothelial cell annexin A2 regulates polyubiquitination and degradation of its binding partner S100A10/p11
    Kai Li He
    Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, New York 10065, USA
    J Biol Chem 283:19192-200. 2008
    ..This mechanism prevents accumulation of free p11 in the endothelial cell and suggests that regulation of tPA-dependent cell surface fibrinolytic activity is precisely tuned to the intracellular level of p11...
  40. doi request reprint Necrotizing soft tissue infection in two patients with multiple myeloma
    Samuel Sultan
    Department of Surgery, Weill Cornell Medical College, New York, New York 10065, USA
    Surg Infect (Larchmt) 12:391-5. 2011
    ..Early diagnosis and treatment is crucial, yet particularly complicated in patients with atypical presentations and impaired host defenses...
  41. ncbi request reprint IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease
    Julia T Geyer
    Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA
    Mod Pathol 27:375-81. 2014
    ..Elevated serum levels of IgG4 is not sufficient to produce the typical disease presentation and should not be considered diagnostic of IgG4-related disease. ..
  42. ncbi request reprint Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells
    Loic Vincent
    Department of Genetic Medicine, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Res 65:3185-92. 2005
    ....
  43. ncbi request reprint A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings
    Edward A Stadtmauer
    Hematology Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Clin Adv Hematol Oncol 5:7-19, quiz 21-2. 2007
  44. ncbi request reprint Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma
    James R Berenson
    Institute for Myeloma Bone Cancer Research, West Hollywood, California 90069, USA
    Cancer 104:2141-8. 2005
    ..Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma...
  45. doi request reprint Aspirin as thromboprophylaxis in myeloma
    Ruben Niesvizky
    Leuk Lymphoma 49:1646-7. 2008
  46. ncbi request reprint Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
    Donna M Weber
    Department of Lymphoma and Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 357:2133-42. 2007
    ..Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma...
  47. doi request reprint The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
    M A Hussein
    Department of Hematologic Malignancies, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Leukemia 22:1479-84. 2008
  48. doi request reprint Re: When you look matters: the effect of assessment schedule on progression-free survival
    Paul G Richardson
    J Natl Cancer Inst 100:373. 2008

Research Grants2

  1. EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)
    Ruben Niesvizky; Fiscal Year: 2007
    ..It is expected that this work will significantly contribute to the care of patients with this disease and other B-cell malignancies. ..
  2. EXPLOITING NOVEL THERAPEUTIC TARGETS IN MULTIPLE MYELOMA (K23M)
    Ruben Niesvizky; Fiscal Year: 2008
    ..It is expected that this work will significantly contribute to the care of patients with this disease and other B-cell malignancies. ..